ANPEP and prostate cancer: Our inhibitor specifically bound to APN-expressing prostate cancer cell lines in vitro, decreasing their clonogenic survival, and was an effective therapeutic, leading to decreased tumor growth in vivo in xenograft models of prostate cancer.